Oncolytics Biotech (NASDAQ:ONCY) Stock Price Down 8.8%

Oncolytics Biotech, Inc. (NASDAQ:ONCY)’s share price traded down 8.8% on Thursday . The stock traded as low as $1.12 and last traded at $1.14, 683,112 shares changed hands during trading. An increase of 186% from the average session volume of 238,455 shares. The stock had previously closed at $1.25.

ONCY has been the subject of several research analyst reports. Roth Capital began coverage on Oncolytics Biotech in a research note on Wednesday, September 4th. They issued a “buy” rating and a $7.00 price objective for the company. ValuEngine downgraded Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. Finally, Zacks Investment Research upgraded Oncolytics Biotech from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Saturday, November 16th.

The firm has a market capitalization of $30.76 million, a PE ratio of -1.39 and a beta of 2.14. The firm’s fifty day moving average price is $0.94 and its 200 day moving average price is $1.12. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.07.

An institutional investor recently bought a new position in Oncolytics Biotech stock. Verition Fund Management LLC purchased a new stake in Oncolytics Biotech, Inc. (NASDAQ:ONCY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 408,838 shares of the company’s stock, valued at approximately $695,000. Verition Fund Management LLC owned about 2.01% of Oncolytics Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.59% of the company’s stock.

About Oncolytics Biotech (NASDAQ:ONCY)

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Recommended Story: How is a price target determined?

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.